CCNI and neoplasm: Focusing on the HLA-A ligands found for an ADAR1 editing site of cyclin I (CCNI R75G), the authors showed that edited CCNI peptides activated tumor-infiltrating lymphocytes from human melanoma tumors, suggesting edited CCNI peptides function as antigenic epitopes in vivo.